
Sign up to save your podcasts
Or


Can pharmacogenomic testing improve the selection and dosing of antidepressants in patients with MDD? In this episode, we explore the findings of the PRIME Care trial and discuss the clinical significance of these tests.
Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D.
By Psychopharmacology Institute4.6
269269 ratings
Can pharmacogenomic testing improve the selection and dosing of antidepressants in patients with MDD? In this episode, we explore the findings of the PRIME Care trial and discuss the clinical significance of these tests.
Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D.

695 Listeners

76 Listeners

494 Listeners

146 Listeners

297 Listeners

3,338 Listeners

159 Listeners

1,354 Listeners

712 Listeners

565 Listeners

471 Listeners

369 Listeners

725 Listeners

190 Listeners

139 Listeners